The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The importance of sequence in rescheduling bevacizumab and chemotherapy administration in the first-line treatment of metastatic colorectal carcinoma (mCRC).
Leonidas Chelis
No relevant relationships to disclose
Nikolaos Xenidis
No relevant relationships to disclose
Kiriakos Amarantidis
No relevant relationships to disclose
Nikolaos Diamantopoulos
No relevant relationships to disclose
Anastasios L. Boutis
No relevant relationships to disclose
Triantafyllia Koukaki
No relevant relationships to disclose
Prodromos Michailidis
No relevant relationships to disclose
Evagelos Christakidis
No relevant relationships to disclose
Athanasios Chalvatzis
No relevant relationships to disclose
Dimitrios Matthaios
No relevant relationships to disclose
Savas Deftereos
No relevant relationships to disclose
Nikos Courcoutsakis
No relevant relationships to disclose
Panagiotis Prassopoulos
No relevant relationships to disclose
Stylianos Kakolyris
No relevant relationships to disclose